所有图片(1)
别名:
(1R,4R,5S)-4-(2-氯乙基)-1-[(S)-(1S)-2-环己烯-1-基羟甲基] -5-甲基-6-氧杂-2-氮杂双环[3.2. 0]庚烷-3,7-二酮, NPI-0052, 盐孢酰胺A
经验公式（希尔记法）:
C15H20ClNO4
推荐产品
质量水平
生物来源
(Salinospora tropica)
检测方案
≥95% (HPLC)
形式
powder
储存条件
desiccated
颜色
white to beige
运输
wet ice
储存温度
−20°C
InChI
1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
InChI key
NGWSFRIPKNWYAO-SHTIJGAHSA-N
应用
Marizomib作为蛋白酶体抑制剂已用于：
- 研究其对胶质母细胞瘤细胞系的影响
- 分析其对鳉鱼脑老化的影响
- 检测其对多发性骨髓瘤细胞中蛋白激酶B(PKB/AKT)水平的影响
生化/生理作用
Marizomib是一种具有抗癌活性的第二代蛋白酶体抑制剂。Marizomib能够不可逆地结合并有效抑制所有三种20S蛋白酶体亚基。
Marizomib（马里佐米）属于天然产物，是一种海洋生物来源的β-内酯-γ-内酰胺。它具有对血液和实体恶性肿瘤的治疗作用。它参与胱天蛋白酶3、8和9活化，增加活性氧(ROS)和促进细胞凋亡。Marizomib可穿过血脑屏障，是治疗原发脑肿瘤的潜力药物。它具有抗肿瘤特性。
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Nancy Levin et al.
British journal of haematology, 174(5), 711-720 (2016-05-11)
Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin-like (CT-L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase-like (C-L) and trypsin-like (T-L) subunits, in
A M Rajan et al.
Blood cancer journal, 6(7), e451-e451 (2016-07-30)
The treatment of multiple myeloma (MM) is rapidly evolving. In the United States, four drugs (panobinostat, ixazomib, daratumumab and elotuzumab) were approved for the treatment of MM in 2015. As a result of improved diagnosis and therapy, there has been
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Kaijun Di et al.
Neuro-oncology, 18(6), 840-848 (2015-12-19)
The proteasome plays a vital role in the physiology of glioblastoma (GBM), and proteasome inhibition can be used as a strategy for treating GBM. Marizomib is a second-generation, irreversible proteasome inhibitor with a more lipophilic structure that suggests the potential
B C Potts et al.
Current cancer drug targets, 11(3), 254-284 (2011-01-21)
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle cell
Erika Kelmer Sacramento et al.
Molecular systems biology, 16(6), e9596-e9596 (2020-06-20)
A progressive loss of protein homeostasis is characteristic of aging and a driver of neurodegeneration. To investigate this process quantitatively, we characterized proteome dynamics during brain aging in the short-lived vertebrate Nothobranchius furzeri combining transcriptomics and proteomics. We detected a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门